ArticleDiscover oncology2025
Big data analysis reveals miR-874 as a suppressor and therapeutic target in the progression from endometriosis to ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study.Hereditas · 2026Article
- Genetic analysis of three familial cases of pure terminal 19p13.3 duplication caused by maternal balanced translocation t(19;21) (p13.3;p12).Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEndometriosis (EMS) is a common chronic gynecological disorder that increases the risk of ovarian cancer by approximately threefold. However, the molecular mechanisms underlying this association remain unclear.
methodsMendelian randomization analysis was used to identify the causal relationship between EMS and ovarian cancer. Differential gene expression analysis was conducted using the cancer genome atlas (TCGA) dataset, grouping samples based on miR-874 expression. EcoTyper analysis was applied to evaluate tumor microenvironment composition concerning miR-874 expression. Weighted gene co-expression network analysis (WGCNA) and miWalk target prediction were used to identify key regulatory targets of miR-874. Single-cell RNA sequencing (scRNA-seq) analysis and ChIP-Seq data mining further elucidated the role of miR-874 in clear cell ovarian cancer (CCOC) pathogenesis.
resultsEMS is a key risk factor for CCOC. Multi-datasets analysis revealed that miR-874 down-regulation is closely associated with EMS occurrence, ovarian cancer progression, and patient survival. A total of 194 differentially expressed genes were identified between the high and low miR-874 expression groups, with key genes such as ASB9, TMSB10P1, SMIM24, and PDLIM4 showing significant changes. Functional analysis revealed enrichment in pathways related to mitochondrial function, cell adhesion, proteasomal degradation, and p53 signaling. Survival analysis demonstrated that down-regulation of genes in the high miR-874 group (ZNF623, NDRG1, ZNF7, MTBP, and PHF20L1) was associated with better prognosis, while up-regulation of genes (PDLIM4 and ECRG4) correlated with poorer survival. EcoTyper analysis identified significant tumor microenvironment changes in the high miR-874 group, with an increased abundance of myoepithelial-like (Endothelial.cells.5) and myofibroblast-like (Fibroblasts.1) cells, and reduced levels of migratory-like fibroblasts (Fibroblasts.8), suggesting a more benign tumor phenotype. WGCNA and miWalk analyses indicated that ZNF217 and NDRG1 are potential regulatory targets of miR-874. scRNA-seq data suggested that ZNF217 and NDRG1 are predominantly expressed in ovarian stromal and immune cells. Further, ChIP-Seq data suggest that ZNF217 may bind to the MTBP promoter, which is associated with the stabilization of MDM2, a key negative regulator of p53. We propose a hypothetical miR-874–ZNF217–MTBP–MDM2–p53 regulatory axis that may contribute to the progression of CCOC.
conclusionThe down-regulation of miR-874 may be involved in the progression from EMS to CCOC. We propose that miR-874 may act as a tumor suppressor in CCOC, potentially through the miR-874–ZNF217–MTBP–MDM2–p53 regulatory axis. This proposed mechanism warrants further experimental validation. Collectively, these results provide preliminary insights into the molecular pathogenesis of EMS-associated CCOC and may inform future efforts to identify prognostic markers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.